These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
173 related items for PubMed ID: 20687221
1. Fatigue in prostate cancer survivors treated with definitive radiotherapy and LHRH analogs. Kyrdalen AE, Dahl AA, Hernes E, Hem E, Fosså SD. Prostate; 2010 Sep 15; 70(13):1480-9. PubMed ID: 20687221 [Abstract] [Full Text] [Related]
2. Fatigue in hormone-naïve prostate cancer patients treated with radical prostatectomy or definitive radiotherapy. Kyrdalen AE, Dahl AA, Hernes E, Cvancarova M, Fosså SD. Prostate Cancer Prostatic Dis; 2010 Jun 15; 13(2):144-50. PubMed ID: 20101260 [Abstract] [Full Text] [Related]
3. Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy. Basaria S, Muller DC, Carducci MA, Egan J, Dobs AS. Cancer; 2006 Feb 01; 106(3):581-8. PubMed ID: 16388523 [Abstract] [Full Text] [Related]
4. Increased risk of metabolic syndrome, diabetes mellitus, and cardiovascular disease in men receiving androgen deprivation therapy for prostate cancer. Kintzel PE, Chase SL, Schultz LM, O'Rourke TJ. Pharmacotherapy; 2008 Dec 01; 28(12):1511-22. PubMed ID: 19025432 [Abstract] [Full Text] [Related]
5. Comparing eccentric resistance exercise in prostate cancer survivors on and off hormone therapy: a pilot study. Hansen PA, Dechet CB, Porucznik CA, LaStayo PC. PM R; 2009 Nov 01; 1(11):1019-24. PubMed ID: 19942188 [Abstract] [Full Text] [Related]
6. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE). Kawakami J, Cowan JE, Elkin EP, Latini DM, DuChane J, Carroll PR, CaPSURE Investigators. Cancer; 2006 Apr 15; 106(8):1708-14. PubMed ID: 16544313 [Abstract] [Full Text] [Related]
7. Association of age and response to androgen-deprivation therapy with or without radiotherapy for prostate cancer: data from CaPSURE. Aaronson D, Cowan J, Carroll P, Konety B. BJU Int; 2010 Apr 15; 105(7):951-5. PubMed ID: 19889066 [Abstract] [Full Text] [Related]
8. Chronic fatigue and its correlates in long-term survivors of cervical cancer treated with radiotherapy. Vistad I, Fosså SD, Kristensen GB, Dahl AA. BJOG; 2007 Sep 15; 114(9):1150-8. PubMed ID: 17655733 [Abstract] [Full Text] [Related]
9. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. Braga-Basaria M, Dobs AS, Muller DC, Carducci MA, John M, Egan J, Basaria S. J Clin Oncol; 2006 Aug 20; 24(24):3979-83. PubMed ID: 16921050 [Abstract] [Full Text] [Related]
10. Prospective evaluation of the prevalence and severity of fatigue in patients with prostate cancer undergoing radical external beam radiotherapy and neoadjuvant hormone therapy. Truong PT, Berthelet E, Lee JC, Petersen R, Lim JT, Gaul CA, Pai H, Blood P, Ludgate CM. Can J Urol; 2006 Jun 20; 13(3):3139-46. PubMed ID: 16813705 [Abstract] [Full Text] [Related]
11. Testosterone recovery following prolonged adjuvant androgen ablation for prostate carcinoma. Pickles T, Agranovich A, Berthelet E, Duncan GG, Keyes M, Kwan W, McKenzie MR, Morris WJ, British Columbia Cancer Agency, Prostate Cohort Outcomes Initiative. Cancer; 2002 Jan 15; 94(2):362-7. PubMed ID: 11900222 [Abstract] [Full Text] [Related]
13. Resistance exercise in men receiving androgen deprivation therapy for prostate cancer. Segal RJ, Reid RD, Courneya KS, Malone SC, Parliament MB, Scott CG, Venner PM, Quinney HA, Jones LW, D'Angelo ME, Wells GA. J Clin Oncol; 2003 May 01; 21(9):1653-9. PubMed ID: 12721238 [Abstract] [Full Text] [Related]
14. The 1999 patterns of care study of radiotherapy in localized prostate carcinoma: a comprehensive survey of prostate brachytherapy in the United States. Lee WR, Moughan J, Owen JB, Zelefsky MJ. Cancer; 2003 Nov 01; 98(9):1987-94. PubMed ID: 14584083 [Abstract] [Full Text] [Related]
15. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. Tsai HK, D'Amico AV, Sadetsky N, Chen MH, Carroll PR. J Natl Cancer Inst; 2007 Oct 17; 99(20):1516-24. PubMed ID: 17925537 [Abstract] [Full Text] [Related]
16. Relationship between bone mineral density and androgen-deprivation therapy in Japanese prostate cancer patients. Yuasa T, Maita S, Tsuchiya N, Ma Z, Narita S, Horikawa Y, Yamamoto S, Yonese J, Fukui I, Takahashi S, Hatake K, Habuchi T. Urology; 2010 May 17; 75(5):1131-7. PubMed ID: 20163839 [Abstract] [Full Text] [Related]
17. Prevalence and predictive factors for the development of de novo psychiatric illness in patients receiving androgen deprivation therapy for prostate cancer. DiBlasio CJ, Hammett J, Malcolm JB, Judge BA, Womack JH, Kincade MC, Ogles ML, Mancini JG, Patterson AL, Wake RW, Derweesh IH. Can J Urol; 2008 Oct 17; 15(5):4249-56; discussion 4256. PubMed ID: 18814813 [Abstract] [Full Text] [Related]
18. Long-term changes in bone mineral density and predicted fracture risk in patients receiving androgen-deprivation therapy for prostate cancer, with stratification of treatment based on presenting values. Wadhwa VK, Weston R, Mistry R, Parr NJ. BJU Int; 2009 Sep 17; 104(6):800-5. PubMed ID: 19338564 [Abstract] [Full Text] [Related]
19. Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation. Demanes DJ, Brandt D, Schour L, Hill DR. Am J Clin Oncol; 2009 Aug 17; 32(4):342-7. PubMed ID: 19398902 [Abstract] [Full Text] [Related]
20. Information needs of men on androgen deprivation therapy. Soeyonggo T, Warde P, Fleshner N, Timilshina N, Alibhai SM. BJU Int; 2012 May 17; 109(10):1503-9. PubMed ID: 21883845 [Abstract] [Full Text] [Related] Page: [Next] [New Search]